EC approves two Novo diabetes products

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said the European Commission approved Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to treat Type I and II diabetes in adults. The pharma plans to launch Tresiba in the U.K. and Denmark this half, and in other European markets throughout 2013 and 2014. Novo, which plans to launch Ryzodeg about a year after Tresiba, said it has not yet determined pricing. Tresiba is a long-acting insulin analog, and Ryzodeg is a combination of 70% Tresiba and 30% Novo's NovoRapid insulin aspart. ...